Vericel CORP

Vericel Corporation announced robust second quarter 2026 financial results, exceeding expectations with a 22% revenue increase and raising full-year guidance, alongside a new $200 million share repurchase program.

Vericel Corporation has updated its bylaws to reflect its relocation to a new global headquarters in Burlington, Massachusetts.

Vericel Corporation announced robust first quarter 2026 financial results, with total revenue up 30% to $68.4 million, and raised its full-year revenue guidance.

Vericel Corporation reported robust financial results for the fourth quarter and full-year 2025, driven by significant revenue and profit growth across its advanced therapies.

Vericel Corporation announced preliminary, unaudited financial results for fiscal year 2025, projecting strong revenue growth and profitability, driven by record MACI performance.

Vericel Corporation announced record third quarter 2025 financial results, driven by strong MACI revenue growth and significant profitability improvements.

Vericel Corporation announced a significant increase in total revenue for the second quarter of 2026, driven by robust performance in its MACI and Epicel product lines, alongside positive operational cash flow.

Vericel Corporation announced a 30.1% increase in total revenue for the first quarter of 2026, driven by significant growth in MACI and Epicel sales.

Vericel Corporation reported a significant turnaround to net income in Q3 2025, driven by robust MACI sales and NexoBrid growth, despite a decline in Epicel revenue.

Vericel Corporation announced a significant increase in total revenue for the first half of 2025, fueled by strong performance in its MACI and NexoBrid products, though the company's net loss widened due to increased operating expenses.

Vericel Corporation's Q1 2025 results show revenue growth driven by MACI and NexoBrid, offset by a decline in Epicel sales, resulting in a net loss of $11.2 million.

Vericel Corporation's Q3 2024 results show a significant increase in revenue, primarily driven by growth in MACI and burn care product sales, alongside the launch of MACI Arthro.

Vericel Corporation achieved significant revenue and net income growth in 2025, fueled by strong MACI sales and NexoBrid expansion, while advancing its product pipeline.

Vericel Corporation achieves profitability in 2024, fueled by strong MACI performance and strategic expansion in sports medicine and burn care markets.

Vericel Corporation's 10-K filing details its 2023 financial performance, product portfolio, and strategic outlook, highlighting growth in MACI sales and the launch of NexoBrid.

Kevin F Mclaughlin, a Director of Vericel Corp, sold 7,000 shares of common stock on August 12, 2026 for $44.53 per share.

Michael Halpin, Chief Operating Officer of Vericel Corp, sold 10,000 shares of common stock on August 3, 2026 for $46.84 per share.

Jonathan Siegal, Principal Accounting Officer of Vericel Corp, sold 4,500 shares of common stock on July 30, 2026 for $48.90 per share.

Jonathan Siegal, an officer at Vericel Corp, reported transactions involving the purchase and sale of company stock, including sales executed under a Rule 10b5-1 trading plan.

Vericel Corp's Chief Financial Officer, Joseph Anthony Mara Jr., has sold 5,000 shares of common stock as part of a pre-arranged trading plan.

Vericel Corp's Chief Medical Officer, Jonathan Mark Hopper, reported transactions involving common stock, including acquisitions under an employee stock purchase plan and sales executed via a Rule 10b5-1 trading plan.

Vericel Corporation achieved record full-year revenue of $276.3 million in 2025, marking its second consecutive year of GAAP profitability and significant growth across its product portfolio.

Vericel Corporation announces its 2025 Annual Meeting of Shareholders to be held virtually on April 30, 2025, with several key proposals for shareholder vote.

Vericel Corporation reports strong financial and business results for 2024, driven by revenue growth and profitability improvements, and anticipates continued growth in 2025.

Vericel Corporation announces its 2024 Annual Meeting of Shareholders to be held virtually on May 1, 2024, with voting open until April 30, 2024.

Vericel Corporation announces a strong financial year in 2023, with significant revenue growth and key business milestones, setting the stage for continued success in 2024.

Soleus Capital Master Fund, L.P. and associated entities have reported beneficial ownership of 2.8% of Vericel Corp. common stock as of June 30, 2026.

Vanguard Capital Management has reported beneficial ownership of 2,603,128 shares of Vericel Corp common stock, representing 5.11% of the class, as of March 31, 2026.

Soleus Capital Master Fund and related entities have reported a 5.0% passive beneficial ownership in Vericel Corp's common stock.

The Vanguard Group has filed an amendment to its Schedule 13G, reporting zero beneficial ownership in Vericel Corp common stock following an internal organizational realignment.

Brown Capital Management, LLC has filed an amendment to its Schedule 13G, disclosing a 3.87% beneficial ownership in Vericel Corporation's common stock.

State Street Corporation has reported a 5.6% beneficial ownership stake in Vericel Corp, holding 2,807,242 shares of common stock as of September 30, 2025.